Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emtricitabine/rilpivirine/tenofovir alafenamide - Gilead Sciences/ Janssen

Next Previous
Search
Drug Profile

Emtricitabine/rilpivirine/tenofovir alafenamide - Gilead Sciences/ Janssen

Alternative Names: FTC/RPV/TAF; Odefsey; R/F/TAF; Rilpivirine/emtricitabine/tenofovir alafenamide; Tenofovir alafenamide/rilpivirine/emtricitabine

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Janssen
  • Class Antiretrovirals; Benzonitrile; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 01 May 2021 Registered for HIV-1 infections (In children, In adolescents, In adults) in Switzerland, prior to May 2021 (PO)
  • 31 Dec 2020 Gilead Sciences has patent protection for emtricitabine/rilpivirine/tenofovir alafenamide in USA and European Union
  • 09 Jan 2019 Gilead completes a phase IIIb trial in HIV-1 infections (Treatment experienced) in USA, Belgium, Canada, France, Germany, Italy, Netherlands, Puerto Rico, Spain, Sweden, Switzerland, United Kingdom (NCT02345252)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top